长春高新(000661.SZ)子公司三价流感病毒裂解疫苗(BK-01佐剂)临床试验申请获批准

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Baike Biological, received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing it to conduct clinical trials for a trivalent influenza virus split vaccine (BK-01 adjuvant) aimed at preventing influenza caused by related virus types [1] Group 1 - The approval is a significant step for the company in advancing its vaccine development pipeline [1] - The clinical trials will focus on the prevention of influenza caused by specific virus strains, indicating a targeted approach in vaccine development [1] - This development aligns with the growing demand for effective influenza vaccines in the market [1]